1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner
In this episode, we tackle the recent papers in t…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
November 13, 20181h 16mExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency.
Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762
Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602
9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6
Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779
Topics
medicineoncologyhealthpolicy